Maternal Infant Child and Youth Research Network (MICYRN)

Regulatory pathways for therapies that are not commercially viable for pediatric rare diseases. Working with federal partners to streamline Health Canada policies and processes related to clinical trials and drug authorization specific to children, specifically Bill C 265: An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access).